HRP20080120T3 - Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze - Google Patents

Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze

Info

Publication number
HRP20080120T3
HRP20080120T3 HR20080120T HRP20080120T HRP20080120T3 HR P20080120 T3 HRP20080120 T3 HR P20080120T3 HR 20080120 T HR20080120 T HR 20080120T HR P20080120 T HRP20080120 T HR P20080120T HR P20080120 T3 HRP20080120 T3 HR P20080120T3
Authority
HR
Croatia
Prior art keywords
optionally substituted
hydrogen
ring
heteroaryl
group
Prior art date
Application number
HR20080120T
Other languages
English (en)
Inventor
F. Claiborne Christopher
J. Payne Lloyd
J. Boyce Richard
B. Sells Todd
G. Stroud Stephen
Travers Stuart
J. Vos Tricia
S. Weatherhead Gabriel
Original Assignee
Millennium Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals filed Critical Millennium Pharmaceuticals
Publication of HRP20080120T3 publication Critical patent/HRP20080120T3/hr
Publication of HRP20080120T5 publication Critical patent/HRP20080120T5/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Small-Scale Networks (AREA)

Abstract

Spoj formule (A):ili njegova farmaceutski prihvatljiva sol, naznačen time, da: Rf1 je vodik ili Rf1i Rf2 zajedno tvore vezu; Rf2 je vodik ili Rf2 tvori vezu s Rf1 ili s Rx;Rx i Ry neovisno jedan o drugome su vodik, fluor ili opcionalno supstituirana C1-6 alifatska skupina, ili Rx i Ry zajedno s atomom ugljika na koji su vezani tvore opcionalno supstituiran tro- do šesteročlani cikloalifatski prsten; ili Rx i Rf2 zajedno tvore vezu; ukoliko Rf1 je vodik, tada je G vodik, opcionalno supstituirana alifatska skupina ili prsten B, ukoliko Rf1 i Rf2 zajedno tvore vezu, tada je G vodik, -OR5, -N(R4)2, -SR5, opcionalno supstituirana alifatska skupina ili prsten B;prsten A je supstituiran ili nesupstituiran petero- ili šesteročlani arilni, heteroarilni, cikloalifatski ili heterociklički prsten; prsten B je supstituiran ili nesupstituiran arilni,heteroarilni, heterociklički ili cikloalifatski prsten; prsten C je supstituiran ili nesupstituiranarilni, heteroarilni, heterociklički ili cikloalifatski prsten; Ra je vodik, -C(O)R1, -CO2R1, -SO2R1 ili C1-3 alifatska skupina koja sadrži od 0 do 2supstituenta neovisno odabrana između R3 ili R7;Re je vodik, -OR5, -N(R4)2, -SR5, -NR4C(O)R5, -NR4C(O)N(R4)2, -NR4CO2R6, -N(R4)SO2R6, -N(R4)SO2N(R4)2ili C1-3 alifatska skupina opcionalno supstituirana s R3 ili R7;R1 je C1-6 alifatska skupina ili opcionalno supstituiran aril, heteroaril ili heterociklička skupina; svaki R3 je neovisno odabran iz grupe koju tvore: -halogen, -OH, -O(C1-3 alkil), -CN, -N(R4)2, -C(O)(C1-3 alkil), -CO2H, -CO2(C1-3 alkil), -C(O)NH2 i -C(O)NH(C1-3 alkil); svaki R4 neovisno je vodik ili opcionalno supstituirana alifatska skupina, aril, heteroaril ili heterociklička skupina;ili dva R4 vezana na isti dušikov atom, zajedno s tim atomom dušika, tvore opcionalno supstituirani petero- do šesteročlani heteroaril ili četvero- do osmeročlani heterociklički prsten koji, osim spomenutog atoma dušika, dodatno u prstenu sadrži 0-2 heteroatoma odabrana od N, O i S; svaki R5 neovisno je vodik ili opcionalno supstituirana alifatska skupina, aril, heteroaril ili heterociklička skupina; svaki R6 neovisno je opcionalno supstituirana alifatska skupina ili arilna skupina; svakiR7 neovisno je opcionalno supstituirana arilna, heterociklička ili heteroarilna skupina. Patent sadrži još 55 patentnih zahtjeva.
HRP20080120TT 2004-05-14 2008-03-19 Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze HRP20080120T5 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57165304P 2004-05-14 2004-05-14
US61722104P 2004-10-08 2004-10-08
PCT/US2005/016445 WO2005111039A2 (en) 2004-05-14 2005-05-12 Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase

Publications (2)

Publication Number Publication Date
HRP20080120T3 true HRP20080120T3 (hr) 2008-04-30
HRP20080120T5 HRP20080120T5 (hr) 2012-07-31

Family

ID=35262144

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20080120TT HRP20080120T5 (hr) 2004-05-14 2008-03-19 Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze
HRP20120785TT HRP20120785T1 (hr) 2004-05-14 2012-10-02 Spojevi i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20120785TT HRP20120785T1 (hr) 2004-05-14 2012-10-02 Spojevi i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze

Country Status (26)

Country Link
US (9) US7572784B2 (hr)
EP (4) EP2261226B1 (hr)
JP (4) JP4467616B2 (hr)
KR (3) KR101792651B1 (hr)
CN (1) CN104193750B (hr)
AR (1) AR049277A1 (hr)
AT (1) ATE381566T1 (hr)
AU (1) AU2005243175B2 (hr)
BR (1) BRPI0511139B8 (hr)
CA (1) CA2565411C (hr)
CY (2) CY1108092T1 (hr)
DE (1) DE602005003951T4 (hr)
DK (1) DK1771450T5 (hr)
EA (1) EA012112B1 (hr)
ES (3) ES2540987T3 (hr)
HK (4) HK1102500A1 (hr)
HR (2) HRP20080120T5 (hr)
IL (1) IL179063A (hr)
MX (1) MXPA06013042A (hr)
MY (1) MY139355A (hr)
NZ (1) NZ551370A (hr)
PL (1) PL1771450T3 (hr)
PT (2) PT1771450E (hr)
RS (2) RS52436B (hr)
TW (1) TWI338688B (hr)
WO (1) WO2005111039A2 (hr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2540987T3 (es) 2004-05-14 2015-07-15 Millennium Pharmaceuticals, Inc. Métodos para preparar inhibidores de la aurora cinasa
CA2582235A1 (en) * 2004-10-04 2006-04-20 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
EP1828165B1 (en) * 2004-10-29 2013-03-20 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
EP1876178B1 (en) 2005-04-28 2015-05-27 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
EP1877098B1 (en) * 2005-05-05 2013-04-24 Chroma Therapeutics Limited Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
EP1978964A4 (en) * 2006-01-24 2009-12-09 Merck & Co Inc JAK2 tyrosine kinase Inhibition
WO2007108936A2 (en) * 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
JP2009530342A (ja) * 2006-03-20 2009-08-27 エフ．ホフマン−ラ ロシュ アーゲー Ｂｔｋおよびｓｙｋ蛋白キナーゼを阻害する方法
CN101432261A (zh) * 2006-05-19 2009-05-13 惠氏公司 作为组织胺-3拮抗剂的n-苯甲酰基-吡咯烷-3-基胺和n-苄基-吡咯烷-3-基胺
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
PE20081152A1 (es) * 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
AU2012203952B2 (en) * 2006-11-16 2014-12-11 Millennium Pharmaceuticals, Inc. Compounds for inhibiting mitotic progression
AU2014280932B2 (en) * 2006-11-16 2016-10-06 Millennium Pharmaceuticals, Inc. Compounds for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
EP2155719A1 (en) * 2007-05-24 2010-02-24 Wyeth LLC Azacyclylbenzamide derivatives as histamine-3 antagonists
TW200914457A (en) * 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
CA2693138A1 (en) * 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
EA201000422A1 (ru) * 2007-09-04 2010-08-30 Биолипокс Аб Бисароматические соединения, применимые при лечении воспаления
MX2010002760A (es) * 2007-09-12 2010-04-01 Wyeth Llc Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3.
TW200918062A (en) * 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
JP2009108036A (ja) * 2007-09-28 2009-05-21 Fujifilm Corp 新規アセチレン化合物、その製造方法、それを構成単位として含むポリマー、該化合物及び／又は該ポリマーを含む組成物、該組成物を硬化させてなる硬化物
GB0803747D0 (en) * 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
WO2009106844A1 (en) * 2008-02-29 2009-09-03 Chroma Therapeutics Ltd. Inhibitors of p38 map kinase
EP2276346B1 (en) 2008-04-30 2016-11-23 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
US20110112193A1 (en) * 2008-05-14 2011-05-12 Peter Nilsson Bis-aryl compounds for use as medicaments
JP5684719B2 (ja) * 2008-12-05 2015-03-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン
MX2011006725A (es) * 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
CA2754946A1 (en) 2009-03-12 2010-09-16 Biolipox Ab Bis aromatic compounds for use as ltc4 synthase inhibitors
US20120035217A1 (en) 2009-03-12 2012-02-09 Biolipox Ab Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors
WO2011110824A1 (en) 2010-03-12 2011-09-15 Biolipox Ab Bis aromatic compounds for use as ltc4 synthase inhibitors
JP2012520276A (ja) 2009-03-12 2012-09-06 バイオリポックス エービー Ｌｔｃ４シンターゼ阻害剤としての使用のためのビス芳香族化合物
US20120004244A1 (en) 2009-03-12 2012-01-05 Biolipox Ab Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8546377B2 (en) * 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
RU2012140021A (ru) 2010-02-19 2014-03-27 Миллениум Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ
TW201316991A (zh) 2011-06-03 2013-05-01 Millennium Pharm Inc Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合
GB201202027D0 (en) * 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN103804391A (zh) * 2012-11-01 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
CN103408552B (zh) * 2013-07-25 2015-07-01 苏州明锐医药科技有限公司 阿立塞替的制备方法
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
JP2018524292A (ja) * 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2020130125A1 (ja) 2018-12-21 2020-06-25 第一三共株式会社 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CN112062768B (zh) * 2020-07-20 2021-08-31 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 具有Aurora激酶降解活性的小分子及其制备方法和应用
EP4450490A1 (en) * 2021-12-14 2024-10-23 Prazer Therapeutics Inc. Novel compound for degrading target protein or polypeptide by using polyubiquitination

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022801A (en) 1974-06-03 1977-05-10 Ciba-Geigy Corporation Pyrazolobenzazepines
US3947585A (en) * 1974-06-03 1976-03-30 Ciba-Geigy Corporation Pyrazolobenzazepines
US4028381A (en) 1975-05-05 1977-06-07 Ciba-Geigy Corporation Pyrazolobenzazepines
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4547581A (en) 1979-02-07 1985-10-15 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines and intermediates in their preparation
KR840000061B1 (ko) 1979-02-07 1984-01-31 에프. 호프만-라 롯슈 앤드 캄파니 아크티엔 게젤샤프트 벤즈아제핀 유도체의 제조방법
ZA80492B (en) * 1979-02-07 1981-01-28 Hoffmann La Roche Benzazepine derivatives
US4318854A (en) 1979-02-07 1982-03-09 Hoffmann-La Roche Inc. Intermediates in the production of 2-benzazepines
NL8000715A (nl) 1979-02-07 1980-08-11 Hoffmann La Roche Pyrimido-2-benzazepinen, werkwijzen ter bereiding ervan, alsmede farmaceutische preparaten, die deze pyrimido-2- benzazepinen bevatten.
US4481142A (en) * 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) * 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
NL8102182A (nl) 1981-05-04 1982-12-01 Philips Nv Kleurenbeeldbuis.
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US6124281A (en) 1996-03-08 2000-09-26 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
TW510902B (en) 1997-09-29 2002-11-21 Meiji Seika Kaisha Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
CN100355750C (zh) * 2000-09-15 2007-12-19 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
ATE326462T1 (de) * 2000-12-21 2006-06-15 Vertex Pharma Pyrazolverbindungen als protein-kinase- inhibitoren
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
WO2003013545A1 (en) 2001-08-09 2003-02-20 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles as endothelin antagonisits
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
ES2540987T3 (es) * 2004-05-14 2015-07-15 Millennium Pharmaceuticals, Inc. Métodos para preparar inhibidores de la aurora cinasa
US8153630B2 (en) 2004-11-17 2012-04-10 Miikana Therapeutics, Inc. Kinase inhibitors
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري

Also Published As

Publication number Publication date
PL1771450T3 (pl) 2008-05-30
US20220041605A1 (en) 2022-02-10
JP4467616B2 (ja) 2010-05-26
EP2746285A1 (en) 2014-06-25
HK1199254A1 (en) 2015-06-26
EP2719698A1 (en) 2014-04-16
MXPA06013042A (es) 2007-02-12
JP2012006972A (ja) 2012-01-12
US20070185087A1 (en) 2007-08-09
DE602005003951T4 (de) 2012-10-11
CA2565411C (en) 2010-04-20
ES2391577T3 (es) 2012-11-27
US8399659B2 (en) 2013-03-19
JP2008285484A (ja) 2008-11-27
AR049277A1 (es) 2006-07-12
EP2746285B1 (en) 2016-09-14
HRP20120785T1 (hr) 2012-11-30
EP2719698B1 (en) 2016-10-05
WO2005111039A2 (en) 2005-11-24
JP5827708B2 (ja) 2015-12-02
KR20130073993A (ko) 2013-07-03
HK1114853A1 (en) 2008-11-14
IL179063A0 (en) 2007-03-08
US20160185782A1 (en) 2016-06-30
EP2261226A1 (en) 2010-12-15
KR20120091275A (ko) 2012-08-17
PT1905773E (pt) 2012-10-25
TWI338688B (en) 2011-03-11
EA200602100A1 (ru) 2007-04-27
AU2005243175B2 (en) 2011-12-01
BRPI0511139B8 (pt) 2021-05-25
MY139355A (en) 2009-09-30
EA012112B1 (ru) 2009-08-28
US20180134716A1 (en) 2018-05-17
HK1205102A1 (en) 2015-12-11
ES2540987T3 (es) 2015-07-15
KR20070011606A (ko) 2007-01-24
JP5148358B2 (ja) 2013-02-20
PT1771450E (pt) 2008-03-31
RS52436B (en) 2013-02-28
BRPI0511139A (pt) 2007-11-27
CN104193750B (zh) 2018-04-27
ATE381566T1 (de) 2008-01-15
TW200604192A (en) 2006-02-01
RS50568B9 (sr) 2019-06-28
US7572784B2 (en) 2009-08-11
DK1771450T3 (da) 2008-04-28
US20090299060A1 (en) 2009-12-03
ES2299080T3 (es) 2008-05-16
US20050256102A1 (en) 2005-11-17
HRP20080120T5 (hr) 2012-07-31
EP2261226B1 (en) 2015-04-01
CN104193750A (zh) 2014-12-10
DE602005003951D1 (de) 2008-01-31
US11014928B2 (en) 2021-05-25
US9765078B2 (en) 2017-09-19
WO2005111039A3 (en) 2006-04-20
DK1771450T5 (da) 2012-01-09
CY1113192T1 (el) 2016-04-13
BRPI0511139B1 (pt) 2019-05-21
EP1771450A2 (en) 2007-04-11
US20200247810A1 (en) 2020-08-06
US20140046055A1 (en) 2014-02-13
KR101748290B1 (ko) 2017-06-16
JP2007537268A (ja) 2007-12-20
US10414770B2 (en) 2019-09-17
RS50568B (sr) 2010-05-07
AU2005243175A1 (en) 2005-11-24
EP1771450B1 (en) 2007-12-19
US20240083906A1 (en) 2024-03-14
CY1108092T1 (el) 2014-02-12
EP1771450B9 (en) 2008-12-24
DE602005003951T2 (de) 2008-12-11
NZ551370A (en) 2009-08-28
RS50568B8 (sr) 2019-08-30
KR101792651B1 (ko) 2017-11-20
IL179063A (en) 2016-05-31
CA2565411A1 (en) 2005-11-24
JP2014114319A (ja) 2014-06-26
HK1102500A1 (en) 2007-11-23
US9102678B2 (en) 2015-08-11

Similar Documents

Publication Publication Date Title
HRP20080120T3 (hr) Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze
AR055053A1 (es) Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas.
RS53734B1 (en) IAP INHIBITORS
RS53788B1 (en) MITOTIC PROGRESSION INHIBITION UNIT
RS52883B (en) HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS
RS51471B (en) BIPHYNYLOXYXIC ACID DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES
HRP20080022T3 (hr) Derivati pirolopiridina i njihova upotreba kao crth2 antagonista
NO20062758L (no) Polycykliske midler for behandling av respiratorisk syncytial virus infeksjoner
RS50045B (sr) Aktivatori glukokinaze
EA200900358A1 (ru) Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
AR053405A1 (es) Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias
HRP20060100T3 (hr) Derivati diaril i arilheteroaril uree kao modulatori 5-ht2a serotonin receptora korisni za profilaksu i liječenje poremećaja povezanih s njima
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
AR064319A1 (es) Compuestos y composiciones farmaceuticas derivadas de sulfonamida ciclicos, proceso de preparacion y usos en el tratamiento de trastornos vasomotrices, sexuales, gastrointestinales y otros
AR055071A1 (es) Derivados de pirrolo (3,2 - b) pirimidina. composiciones farmaceuticas.
RS52451B (en) PHENYLPROPIONAMIDE COMPOUNDS AND THEIR USE
EA200600509A1 (ru) Соединения пиримидотиофена
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
CA2324418A1 (en) Novel opiate compounds, methods of making and methods of use
RS53061B (en) INHIBITORI PROTEIN KINAZE
AR015512A1 (es) Derivados ciclicos n-acilo amina, un procedimiento para su preparacion, un intermediario y una composicion farmaceutica
RS50955B (sr) Derivati ksantina, njihovo dobijanje i njihova primena kao lekova
PE20020220A1 (es) Compuestos de nitrilo de dipeptido como inhibidores de catepsina k
RS51450B (en) 11-BETA-HYDROXISTEROID DEHYDROGENENE INHIBITORS 1
HRP20040073B1 (hr) Inhibitori virusne polimeraze